000293338 001__ 293338
000293338 005__ 20250725103649.0
000293338 0247_ $$2doi$$a10.1182/bloodadvances.2024013086
000293338 0247_ $$2pmid$$apmid:39293081
000293338 0247_ $$2ISSN$$a2473-9529
000293338 0247_ $$2ISSN$$a2473-9537
000293338 0247_ $$2altmetric$$aaltmetric:173595522
000293338 037__ $$aDKFZ-2024-01886
000293338 041__ $$aEnglish
000293338 082__ $$a610
000293338 1001_ $$aUnglaub, Julia Marie$$b0
000293338 245__ $$aVenetoclax-based salvage therapy as bridge-to-transplant is feasible and effective in patients with relapsed/refractory AML.
000293338 260__ $$aWashington, DC$$bAmerican Society of Hematology$$c2025
000293338 3367_ $$2DRIVER$$aarticle
000293338 3367_ $$2DataCite$$aOutput Types/Journal article
000293338 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1739177634_9306
000293338 3367_ $$2BibTeX$$aARTICLE
000293338 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000293338 3367_ $$00$$2EndNote$$aJournal Article
000293338 500__ $$a2025 Jan 28;9(2):375-385
000293338 520__ $$aThe BCL2-inhibitor Venetoclax (VEN) in combination with hypomethylating agents (HMA) has been approved for first-line treatment of acute myeloid leukemai (AML) patients ineligible for intensive treatment. Emerging Data suggest that VEN containing treatment strategies may also be effective in relapsed/refractory (R/R) AML, however, comparative studies with conventional treatment strategies for medically fit patients as a bridge-to transplant strategy are limited. Using propensity score matching (PSM) analysis, we compared 37 R/R AML patients, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic cell transplantation (allo-HCT) with 90 patients from the German Study Alliance Leukemia (SAL) AML registry, who were treated with non-VEN-containing salvage therapy according to their treating physician's choice (TPC) including intensive and non-intensive protocols. The overall response rate (ORR=CR+CRi) among all VEN patients was significantly higher compared to the TPC control cohort (62% vs. 42%; p=0.049). Overall, 73% of VEN-treated patients vs. 63% of TPC patients were successfully bridged to allo-HCT (p =0.41). After a median follow-up of 34.3 months for the VEN cohort and 21.0 months for the TPC cohort, the median overall-survival (OS) was 15.8 months (95%-CI, 10.6-NE) and 10.5 months (95%-CI, 6.8-19.6) (p=0.15), respectively. PSM revealed a trend towards improved OS for VEN patients (HR 0.70; 95%-CI, 0.41-1.22; p=0.20). Median event free survival (EFS) was significantly longer in the VEN cohort (8.0 months) compared to the TPC cohort (3.7 months) (p=0.006). In summary, our data suggests that VEN-based salvage therapy is a safe and effective bridge to allo-HCT for this difficult-to-treat AML patient population.
000293338 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000293338 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000293338 7001_ $$0P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aSchlenk, Richard$$b1$$udkfz
000293338 7001_ $$aMiddeke, Jan M$$b2
000293338 7001_ $$00000-0002-5259-4651$$aKrause, Stefan W$$b3
000293338 7001_ $$aKraus, Sabrina$$b4
000293338 7001_ $$aEinsele, Hermann$$b5
000293338 7001_ $$aKramer, Michael$$b6
000293338 7001_ $$00000-0002-1811-4562$$aZukunft, Sven$$b7
000293338 7001_ $$aKauer, Joseph$$b8
000293338 7001_ $$aRenders, Simon$$b9
000293338 7001_ $$aKatelari, Elena$$b10
000293338 7001_ $$aSchliemann, Christoph$$b11
000293338 7001_ $$aPabst, Caroline$$b12
000293338 7001_ $$aLuft, Thomas$$b13
000293338 7001_ $$00000-0002-7429-8570$$aDreger, Peter$$b14
000293338 7001_ $$00000-0002-3791-0548$$aRöllig, Christoph$$b15
000293338 7001_ $$aBornhäuser, Martin$$b16
000293338 7001_ $$aMüller-Tidow, Carsten$$b17
000293338 7001_ $$aSauer, Tim$$b18
000293338 773__ $$0PERI:(DE-600)2876449-3$$a10.1182/bloodadvances.2024013086$$gp. bloodadvances.2024013086$$n2$$p375-385$$tBlood advances$$v9$$x2473-9529$$y2025
000293338 8564_ $$uhttps://inrepo02.dkfz.de/record/293338/files/blooda_adv-2024-013086-main.pdf
000293338 8564_ $$uhttps://inrepo02.dkfz.de/record/293338/files/blooda_adv-2024-013086-main.pdf?subformat=pdfa$$xpdfa
000293338 909CO $$ooai:inrepo02.dkfz.de:293338$$pVDB
000293338 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000293338 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000293338 9141_ $$y2024
000293338 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD ADV : 2022$$d2023-08-25
000293338 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000293338 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000293338 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000293338 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-25
000293338 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000293338 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000293338 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-25
000293338 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-25
000293338 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000293338 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000293338 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000293338 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBLOOD ADV : 2022$$d2023-08-25
000293338 9201_ $$0I:(DE-He78)W010-20160331$$kW010$$lKlinische Studienzentrale$$x0
000293338 980__ $$ajournal
000293338 980__ $$aVDB
000293338 980__ $$aI:(DE-He78)W010-20160331
000293338 980__ $$aUNRESTRICTED